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Summary 
The development of autoimmune disease is accompanied by the acquired recognition of new 
self-determinants, a process commonly referred to as determinant spreading. In this study, we 
addressed  the  question  of whether  determinant  spreading  is  pathogenic  for progression  of 
chronic-relapsing experimental autoimmune  encephalomyelitis  (EAE),  a  disease  with  many 
similarities  to multiple sclerosis  (MS).  Our approach involved a systematic epitope mapping of 
responses to myelin proteolipid protein (PLP) as well as assaying responses to known encephal- 
itogenic determinants of myelin basic protein (MBP 87-99) and myelin oligodendrocyte g|yco- 
protein (MOG 92-106) at various times after induction of EAE in (SWRXSJL)F1 mice immu- 
nized with PLP 139-151. We found that the order in which new determinants are recognized 
during the course of disease follows a predictable sequential pattem. At monthly intervals after 
immunization with p139-151, responses to PLP 249-273, MBP 87-99, and PLP 173-198 were 
sequentially accumulated in all mice examined. Three lines of evidence showed that determi- 
nant spreading is pathogenic for disease progression: (a) spreading determinants mediate passive 
transfer of acute EAE in naive (S'W~￿  1 recipients; (b) an invariant relationship exists be- 
tween the development of relapse/progression and the spreading of recognition to new immu- 
nodominant encephalitogenic determinants; and (c) after EAE onset, the induction ofpeptide- 
specific tolerance to spreading but not to nonspreading encephalitogenic determinants prevents 
subsequent progression of EAE. Thus, the predictability of acquired self-determinant recogni- 
tion provides a basis for sequential determinant-specific therapeutic intervention after onset of 
the autoimmune disease process. 
E 
xperimental autoimmune  encephalomyelitis (EAE)  1 is 
an animal model commonly used in multiple sclerosis 
(MS) research. EAE is induced by immunization of animals 
with myelin proteins,  and  clinical disease  develops when 
primed  CD4 +  T  cells  enter  the  central  nervous  system 
(CNS)  and  recognize  encephalitogenic  peptide  determi- 
nants presented in the context of class II MHC molecules. 
Perivascular inflammation  often leads  to  clinical  paralysis 
and demyelination. In SjL/j, swR/j,  and  (SWRXSJL)F1 
mice, recovery from the primary attack is followed by a re- 
lapsing-remitting  pattern  of  disease  with  a  subsequent 
chronic progression of disability reminiscent of MS. How- 
1Abbreviations used in this paper: CNS, cental nervous system; DTH, de- 
layed-type hypersensitivity;  EAE, experimental  autoimmune encephalo- 
myelitis; MBP, myelin  basic protein; MOG, myelin  oligodendrocyte  gly- 
coprotein; MS, multiple sclerosis; PLP, proteolipid  protein. 
ever,  the  underlying  cause  for relapse  and  chronicity in 
both MS and EAE are presently unclear. 
Recent studies have suggested that acquired recognition 
of new self-determinants, a process commonly referred to 
as determinant spreading, may be implicated in relapse and 
disease progression. McCarron et al. (1) showed that during 
relapse,  (SJL￿  1 (H-2  s,u) mice  acquire  a  new  class II 
MHC-restricted response to  myelin basic  protein  (MBP) 
that was not apparent during the primary inflammatory at- 
tack.  Clayton  et  al.  (2)  found  that  B10.PL  (H-2  u)  mice 
made  neonatally  tolerant  to  the  immunodominant  IA  u- 
restricted pl-9  determinant of MBP remain susceptible to 
disease induction with intact MBP containing a nondomi- 
nant  IEU-restricted second  determinant,  p35-47.  Further- 
more, Lehmann et al. (3) showed that immunoreactivity to 
the  nondominant determinants MBP 35-47,  81-100,  and 
121-140 occurs during the development of chronic EAE in 
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the  immunodominant  IAU-restricted  determinant  p1-11. 
Intermolecular spreading to proteolipid protein  (PLP) was 
demonstrated by Perry et al.  (4)  in mice immunized with 
MBP, while Cross et al.  (5) showed that such intermolecu- 
lar spreading generates encephalitogenic T  cells with newly 
acquired  antigen  specificity.  Most  recently,  McRae  et  al. 
(6) inhibited the progression ofpl39-151-induced EAE by 
inducing tolerance  to whole  PLP after recovery from the 
primary  attack.  These  data  suggest  that  spreading  to  new 
PLP determinants  may provide a basis for peptide-specific 
therapy after disease onset. 
In this study, we have extended these earlier findings by sys- 
tematically assessing the pattern ofintra- and intermolecular 
determinant spreading as a function of time in (SWR￿ 
mice immunized with the immunodominant PLP 139-151 
encephalitogen.  We  report  that  the  order  in  which  new 
determinants  are  recognized  during  the  course  of disease 
follows an ordered,  predictable,  sequential  pattern.  More- 
over, an invariant relationship  exists between the develop- 
ment  of relapse/progression  and  spreading  of recognition 
to  new  immunodominant  encephalitogenic  determinants. 
Finally,  we show that peptide-specific  treatment  with  the 
primary spreading determinant  after disease  onset prevents 
subsequent chronic progression ofEAE. These data support 
the view that determinant spreading is a pathogenic process 
that  leads  to  relapse  and  chronic  progression  of autoim- 
mune disease, and that the predictable sequential pattern of 
spreading provides the basis for peptide-specific therapy af- 
ter the onset of clinical disease. 
Materials  and Methods 
Mice.  Female  (SWR.XSJL)F1 (H-2  q's) mice were bred at the 
Research Institute  of the Cleveland Clinic Foundation by mating 
SW1L/J  (H-2q) females with SJL/J  (H-2  s) males purchased from 
The Jackson Laboratory (Bar Harbor,  ME).  Mice were immu- 
nized at 7-12 wk of  age. All protocols for animal research met with 
prior approval of the Animal Research Committee of the Cleve- 
land  Clinic  Foundation  in  compliance with  the  Public  Health 
Service policy on humane care and use of laboratory animals. 
Bulk Peptide  Synthesis.  The  PLP peptides  104-117  KTTIC- 
GKGLSATVT, 139-151 HSLGKWLGHPDKF (serine for cysteine 
at residue 140), 178-191 NTWTTCQSIAFPSK, and 258-273 IAA- 
TYNFAVLKLMGR.G as well as MBP 87-99 VHFFKNIVTPRTP 
and  MOG  92-106  DEGGYTCFFRDHSYQ were  either  pur- 
chased  commercially  (Bio-Synthesis,  Lewisville,  TX)  or  were 
synthesized  manually as  previously described  (7)  with  standard 
solid-phase  methodology using side chain-protected t-Boc amino 
acids  (Peninsula  Laboratories  Inc.,  Belmont,  CA).  All  peptides 
were  purified  >90%  by  reverse-phase  HPLC  using  a  22  ￿ 
250-ram  C-18  column  (Vydac  Separations  Group,  Hesperia, 
CA). The identity of purified peptides  was confirmed by amino 
acid analysis. 
Active EAE Induction.  EAE was induced as previously described 
(7). (SWR￿  mice were immunized by subcutaneous injec- 
tion in the abdominal flanks on day 0 with 100 nm of PLP 139- 
151  peptide  (154  b~g) and  400  ~g  Mycobacterium  tuberculosis 
H37RA (Difco Laboratories  Inc., Detroit,  MI) in 200 Ixl of an 
emulsion of equal volumes of water and IFA (Difco Laboratories 
Inc.).  On days 0 and 3, each mouse also received 0.6 X  l0 t(} i.v. 
Bordetella pertussis  bacilli (Michigan Department of Public Health, 
Lansing,  MI).  In  this  study,  all  mice  developed  clinical  EAE 
within 30 d after immunization. 
Clinical and Histologic Evaluation.  All mice were weighed and 
examined  daily  for neurologic signs as previously described  (7) 
according to the following criteria:  0, no disease; l, decreased  tail 
tone or slightly clumsy gait; 2, tail atony and/or moderately clumsy 
gait and/or poor righting ability; 3, limb weakness; 4, limb paral- 
ysis; 5, moribund state. The presence of relapse was determined 
when mice showed an increase in observed neurologic disability 
of at least one clinical score unit.  The increased  neurologic deficit 
was  typically  accompanied by an  abrupt  and substantial  (~7%) 
weight loss. Brains and spinal cords were fixed in 10% phosphate- 
buffered formalin,  and paraffin-embedded sections  were stained 
with  luxol  fast blue  and  counterstained  with  hematoxylin  and 
eosin.  The presence of inflammatory loci,  cellular infdtrates,  and 
demyelination  in  CNS  meninges  and  parenchyma  was  deter- 
mined under light microscopy. 
PLP Pin Peptides.  A PLP pin peptide series (see Fig.  1) effec- 
tively representing a walkthrough of the entire  276-amino acid 
primary sequence of mouse PLP (8, 9) was purchased from Chi- 
ron Mimotopes (San Diego, CA). A total of 265 overlapping 12- 
mers were synthesized  on high density polyethylene rod tips as- 
sembled  into holders designed  in 96-well microtiter plate format 
(10). When Fmoc biochemistry is used in the synthesis, cleavage 
of one peptide per microtiter well can occur (11, 12). Similar pin 
series have been used successfully to map T cell determinants  of  hen 
egg white lysozyme (12), MBP (3,  13), and glutamic acid decar- 
boxylase  (14).  Upon arrival,  1 txg of each PLP pin peptide was 
dissolved  in  500  6xl  of a  solution  of 40%  acetonitrile  (Aldrich 
Chemical  Co.,  Milwaukee,  WI)  in  10  mM  Hepes  buffer 
(GIBCO BRL, Gaithersburg,  MD). Working aqueous concentra- 
tions of  pin peptides  were prepared at 150 txg/ml in PBS, pH 7.2, 
and 20 I-d of each working solution was distributed  sequentially 
into individual  wells of 96-well flat-bottomed microtiter Falcon 
plates  (Becton Dickinson & Co., Lincoln Park,  NJ).  The plates 
were stored at -20~  until ready for use. 
Determinant Spreading during EAE.  At days 7,  28,  56,  and 84 
after immunization of (SWR ￿  SJL)  F1 mice with p 139-151, spleen 
cells were tested for proliferative  responses to the 265 overlapping 
PLP pin peptides,  to MBP 87-99, an immunodominant encepha- 
litogenic determinant  for both  SJL/J  (15,  16)  and SWtL/J  (17) 
mice,  and to myelin oligodendrocyte glycoprotein (MOG)  92- 
106,  an  immunodominant  encephalitogen  for SjL/j  mice  (18). 
Mononuclear cells were separated  from single-cell  suspensions by 
centrifugation on Lympholyte-M (Accurate  Chemical & Science 
Corp., Westbury, NY) for 20 rain at 2,500 rpm. Cells collected 
from the interface  were washed three  times  in HBSS  (GIBCO 
BRL) and resuspended  in serum-free HL-1 media (Hycor, Irvine, 
CA) supplemented with 2 mM fresh r-glutamine, 100 U/ml pen- 
icillin,  100  ~g/ml  streptomycin,  and  30  mM  Hepes  buffer 
(GIBCO BILL). Each well contained 2 ￿  105 spleen cells with 15 
Ixg/ml pin peptide in a total volume of 200 Ixl. Triplicate  wells 
containing 15  txg/ml MBP 87-99 and MOG 92-106 were also 
tested.  Triplicate  positive  control  wells  contained  anti-mouse 
CD3 antibody at 10 I~g/ml (PharMingen, San Diego, CA) or 20 
txg/rnl M.  tuberculosis H37RA (Difco Laboratories  Inc.), whereas 
negative  control wells contained either no peptide or 1 of 30 ir- 
relevant  pin peptides  of myohemerythrin, a protein having mini- 
mal  sequence  homology with  myelin  proteins  (19).  Dose  re- 
sponses to whole PLP (0.1-100 Ixg/ml) were also assessed in each 
experiment. The PLP was prepared from a washed total lipid ex- 
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to aqueous form as previously described (7). Cultures were incu- 
bated at 37~  in humidified air containing 5% CO  2. At 4 d, cul- 
tures were pulsed with [methyl-3H]thymidine (1.0 p~Ci/well, sp 
act 6.7 Ci/mmol; New England Nuclear, Boston,/VIA),  and the 
cells were harvested after 16 h by aspiration onto glass fiber filters. 
Levels of incorporated radioactivity were determined by scintilla- 
tion spectrometry.  Test wells  containing 15  p,g/ml of peptide 
were  considered positive when  their stimulation index was  at 
least two times both the SD and the mean proliferation of control 
wells without peptide.  Identification of PLP antigenic determi- 
nants required that positive proliferative  responses be generated 
by at least three adjacent overlapping 12-mers. Responses to irrel- 
evant myohemerythrin peptides were  never observed,  and re- 
sponses to PLP peptides did not occur in naive mice or in control 
mice immunized with BSA.  Responses to whole PLP were in- 
consistent between and within different  preparations and often 
did not accompany marked responses to immunodominant  PLP 
determinants. 
T Cell Lines and T Cell Assays.  To determine the activation pro- 
file of the novel spreading determinant PLP 258-273, short-term 
(SWR￿  T cell lines were generated to the immunodomi- 
nant p139-151 and to the nonencephalitogenic  p258-273 as pre- 
viously described (21). LN cells from day 10 peptide-primed mice 
were  cultured at  2.5  X  106  cells/ml in 24-well flat-bottomed 
plates (Falcon Labware,  Becton Dickinson & Co.) in a total vol- 
ume of 2.0  ml/well of DMEM  (GIBCO BILL) supplemented 
with 10% fetal bovine serum (Hyclone Laboratories  Inc., Logan, 
UT), 2 mM fresh L-glutamine, 100 U/ml penicillin, 100 p~g/ml 
streptomycin, 30 mM Hepes buffer,  5 ￿  10 -5 M  2-ME, and 20 
p,M peptide. After 3-4 d of stimulation, cells were centrifuged on 
Lympholyte-M, washed and rested without antigen in culture me- 
dia supplemented with 20 U/ml recombinant mouse IL-2 (Phar- 
Mingen)  and  2  ￿  106/ml  x-irradiated  (2,000  rads) syngeneic 
spleen cells. Cells at 4-5 X  10S/ml were rested in 24-well plates 
for 10-14 d receiving fresh IL-2 every other day. The rested cells 
were harvested,  centrifuged on Lympholyte-M, and restimulated 
with 20 p,M peptide.  For adoptive transfer,  5  ￿  105 cells/well 
were cultured with 4 ￿  106 x-irradiated (2,000 rads) (SWRXSJL)F 1 
spleen feeder cells in 24-well plates. At 3 d, cells were harvested, 
centrifuged on Lympholyte-M, and injected into tail veins of na- 
ive x-irradiated (450 fads) (SWRXSJL)F1  recipients.  Supemates 
from some cultures were removed at 48 h for cytokine ELISA as- 
says. For T  cell assays, dose-response studies were performed us- 
ing 5  ￿  104 line cells/microtiter well with 5  ￿  l0  s x-irradiated 
(2,000 rads) spleen feeder monolayers from either SWR/J, SJL/J, 
or (SWR￿  mice. Cells were pulsed at 48 h, harvested  16 h 
later,  and processed  for  scintillation spectrometry as  described 
above. Splenocyte proliferative  responses to p139-151 and MBP 
87-99  were  determined in  (SWR￿  1 mice  tolerized after 
EAE  onset  by  intraperitoneal immunization with  either  the 
spreading MBP 87-99 determinant or the nonspreading  PLP 104- 
117 determinant. Spleen cells at 3  ￿  10S/well were cultured in 
96-well flat-bottomed microtiter plates in DMEM supplemented 
as described  above. The final volume for each  culture was 200 
p,1/well.  Dose-response  profiles  to  each  peptide  were  deter- 
mined. At 72 h, cultures were pulsed with tritiated thymidine and 
harvested  16  h  later for scintillation spectrometry as  described 
above. 
ELISAs.  Purified anti-mouse cytokine capture/detection an- 
tibody pairs  were  purchased  from  PharMingen.  The  capture/ 
detection antibody pairs used in this study included anti-mouse 
IFN-~/  (R4-6A2 and biotin-XMG1.2), anti-mouse IL-2 (JES6- 
1A12 and biotin-JES6-5H4), anti-mouse IL-4 (BVD4-1Dll and 
biotin-BVD6-24G2), and anti-mouse IL-10 (JES5-2A5  and bi- 
otin-SXC-1). 50 p,1 of coating buffer (0.1 M NaHCO3, pH 8.2) 
containing capture antibody at 4 p~g/ml was added to each  mi- 
crotiter well in 96-well enhanced protein binding ELISA plates 
(Coming Glass Inc., Coming, NY). After overnight incubation  at 
4~  plates were washed with PBS/Tween (0.5%) and blocked by 
adding 200 p,1/well of PBS containing  3% BSA. Plates were incu- 
bated for 2 h at room temperature and washed.  100 g,1 of recom- 
binant cytokine standards  (PharMingen) at multiple concentra- 
tions and  100  g,1  of each  test  sample  were  added  to  duplicate 
wells. After incubation for 4 h at room temperature and washing, 
100 p~l of appropriate  detection antibody at 2 p~g/ml was added to 
duplicate wells for 45 rain at room temperature. After washing, 
100 p,1 of a 1:400 dilution ofavidin peroxidase  (Sigma Chemical 
Co., St. Louis, MO) was added to each well and incubated for 30 
rain at room temperature. Plates were washed,  and each well re- 
ceived 100 p~l of fresh substrate buffer containing 300 p,g/ml of 
the substrate 2,2"-azino-bis(3-ethylbenzthiazollne-6-sulfonic  acid) 
(ABTS;  Sigma Chemical Co.) and 0.03% H202 in 0.1  M  citric 
acid  at pH  4.35.  After 12 rain, the absorbance at 405  nm was 
measured using an ELISA microplate autoreader (Bio-Tek Instru- 
ments, Inc., Winooski, VT). Standard values were plotted as ab- 
sorbance (optical density) vs cytokine concentration, and sample 
cytokine concentrations were  determined as  values  within the 
linear part of the standard curve. 
Passive Transfer of EAE with Spreading Determinants.  50  d  after 
immunization with p139-151,  spleen cells from (SWR￿  1 
EAE mice were stimulated in vitro with 20 p,M of either p139- 
151 or the spreading determinant MBP 87-99. 3 d after activation, 
the  cells were centrifuged on Lympholyte-M, washed,  and in- 
jected into tail veins of naive x-irradiated  (450 rads) (SWR￿  1 
mice. Mice were assessed daily for clinical  signs of EAE as de- 
scribed above. 
Hemisplenectomy.  28  d  after  immunization with  p139-151, 
(SWR￿  mice were anesthetized  by subcutaneous injection 
of 200 p,g/kg ketamine (Fort Dodge Laboratories,  Fort Dodge, 
IA)  and 10  ~g/kg xylazine (Miles Laboratories,  Shawnee Mis- 
sion, KS), and an incision was made in the shaved left abdominal 
flank under sterile conditions. Half of the spleen was removed for 
immunologic testing using a battery operated cauterizer 0orgensen 
Laboratories,  Loveland, CO),  which  kept  bleeding to  a  mini- 
mum. Care was taken to avoid obstruction to blood flow through 
the splenic artery and vein. The abdominal wall was closed with 
4.0 silk suture, and the skin was closed with wound clips. Hemi- 
splenectonfized mice were weighed and examined daily for neu- 
rologic signs and were killed on day 84 for retesting autoreactive 
immune responses using the remaining half of the spleen. 
Induction of Peptide-specific Tolerance.  10 d after onset of EAE, 
(SWR￿  mice were  tolerized to  either PLP  104-117  or 
MBP 87-99 by one of two methods:  (a)  tail  vein injection of 
300  p,g of peptide in 0.2  ml PBS  according to previously de- 
scribed procedures  (22, 23); or (b) intraperitoneal injection of 100 
p,g peptide in 0.2 ml of an emulsion containing equal volumes of 
aqueous peptide and IFA. The latter method has been described 
previously (2, 24) and has been recendy shown in adult mice to 
induce a splenic  CD4 + Th2 Ag-specific  response  involving the 
production of IL-5 and IL-10 (25). All mice were subsequently 
weighed and evaluated daffy by an investigator blinded to the tol- 
erance protocols. 
Delayed-type Hypersensitivity (DTH) Ear Swelling.  Determinant- 
specific DTH reactions  were quantitated as previously described 
(26). At 56 d after EAE onset,  (SWR￿  mice tolerized to 
1779  Yu et al. PLP 104-117 and MBP 87-99 were challenged by injecting 10 ~1 
PBS containing 10 p.g ofp139-151 in the dorsal surface of  the ear 
using a  100-1*1 Hamilton syringe  and a 30-gauge needle.  Con- 
tralateral ears were injected similarly with PBS containing 10 }xg 
of  MBP 87-99. Ear thickness was measured three times before in- 
jection and three more times 24 h after challenge  using an engi- 
neer's micrometer  (Mitutoyo model 7326;  Schlesinger's  Tools, 
Brooklyn, NY).  Increases  in peptide-specific  ear  swelling  were 
determined and expressed in units of 10 -4 inches  +  SE. 
Statistical Analysis.  Student's t-test was used to analyze differ- 
ences  in DTH,  proliferation,  and mean clinical  scores between 
PLP 104-117- and MBP 87-99-tolerized mice. 
Results 
Sequential Pattern of Determinant Spreading  during EAE Pro- 
gression.  Determinant spreading was evaluated in (SWR￿ 
SJL)F 1 mice  immunized  with  the  immunodominant  PLP 
139-151  determinant.  In  three  independently  performed 
experiments,  spleens  were  removed  from  one  mouse  on 
days 7,  28,  56,  and  84  after  p139-151  immunization  and 
tested for proliferative responses to a pin series of PLP pep- 
tides.  The pin series consisted of 265  overlapping 12-mers 
of PLP, each differing by one additional amino acid at the 
COOH-terminus and one deleted amino acid at the NH2- 
terminus (Fig. 1). Intermolecular determinant spreading was 
evaluated by measuring responses to the immunodominant 
determinants  MBP 87-99 (15-17) and MOG 92-106 (18). 
PLP  Sequence 
140  150  160  170 
1 ....  HCLGKWLGHPDKFVGITYALTVVWLLVFACSAV  .... 276 
1 ....  HCLGKWLGHPDK 
CLGKWLGHPDKF 
LGKWLGHPDKFV 
GKWLGHPDKFVG 
KWLGHPDKFVGI 
WLGHPDKFVGIT 
LGHPDKFVGITY 
GHPDKFVGITYA 
HPDKFVGITYAL 
PDKFVGITYALT 
DKFVGITYALTV 
KFVG I  TYALTVV 
FVGI  TYALTVVW 
VG  I  TYALTVVWL 
GITYALTVVWLL 
ITYALTVVWLLV 
TYALTVVWLLVF 
YALTVVWLLVFA 
ALTVVWLLVFAC 
LTVVWLLVFACS 
TVVWLLVFACSA 
VVWLLVFACSAV  .... 276 
Figure 1.  Epitope-mapping pin peptide series for PLP. An overlapping 
series of 12-mer peptides effectively representing a walkthrough of the 
entire 276 amino acid primary sequence of mouse PLP was used to mea- 
sure determinant spreading during the course of EAE in (SWR￿  1 
mice. In addition, dose-response profiles were also determined for reac- 
tivity to the SjL/j encephalitogenic determinants MBP 87-99 and MOG 
92-106. 
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Responses  to  the  priming  determinant  p139-151  were 
readily apparent in all mice on all days tested and were of- 
ten  characterized by plasticity  of determinant  recognition 
involving reactivity to peptide  regions directly adjacent  to 
the  defined  p139-151  immunogen  (Table  1).  On  day  7, 
two of three mice responded to PLP 152-174, a region di- 
rectly adjacent to the COOH-terminus ofp139-151, whereas 
on day 84 two of three mice responded to a peptide region 
flanking the NH2-terminus ofp139-151. 
Clinical  EAE  occurred within  19-30  d  after  p139-151 
immunization. All mice tested after day 7 had chnical EAE, 
and all mice tested after day 28 developed at least one clin- 
ical EAE exacerbation. On days 28, 56, and 84 a sequential 
accumulation  of  responses  developed  to  PLP  249-273, 
MBP  87-99,  and PLP  173-198,  respectively  (Table  1).  In 
addition,  one mouse responded to PLP 47-60 ETYFSKN- 
YQDYEYL on day 56. The failure to observe reactivity to 
this determinant before or at any other time thereafter sug- 
gests that such ephemeral determinant recognition may re- 
flect  aborted  autoreactivity.  A  response  to  MOG  92-106 
was  observed in  one  mouse  on day  84  only.  Plasticity  of 
recognition was also apparent in reactivity to spreading de- 
terminants,  particularly  in  response  to flanking regions  of 
the defined p178-191 encephalitogen (27) on day 84. Thus, 
broad regional  recognition  of core  and  flanking  determi- 
nants appears to be a characteristic of early self-recognition 
events  initiated  by  exogenous  priming  or  endogenous 
spreading. The combined results ofintra- and intermolecu- 
lar determinant spreading are summarized in Table 2. 
PLP 249-273  Is a Nonencephalitogenic  Determinant Involved 
in Spreading.  The observed autoreactivity to p249-273 was 
novel and was further examined.  PLP 258-273  IAATYN- 
FAVLKLMGP-,G was synthesized and used as an immuno- 
gen in  (SWR￿  mice.  Despite  extensive  efforts,  we 
were unable to induce histologic or clinical EAE by either 
active  immunization  or  passive  transfer  with  p258-273- 
primed T  cells  (data not shown). A  similar observation re- 
garding an overlapping PLP sequence was made  by Greet 
et al.  (28) in the parental SJL/J strain. 
The failure  to observe p258-273-mediated  disease  may 
be due to inherent activation defects since primed LNC ac- 
tivated  by p258-273  showed  deficient  production  of in- 
flammatory Thl  cytokines when  compared with  produc- 
tion  by  p139-151-activated  primed  LNC  (Fig.  2  A). 
Responses to p258-273 were restricted by both MHCq and 
MHC  s, and proliferation ofp258-273-pfimed (SWR￿  1 
T  cell hnes with (SWRXSJL)F1 APC appeared to comprise 
the  additive  responses  of cultures  containing splenic  APC 
from parental SWR/J (H-2q) and SJL/J (H-2  s) mice (Fig. 2 
B). Thus, p258-273 appears to be a nondominant,  nonen- 
cephalitogenic  promiscuous  determinant  of PLP  consis- 
tendy involved in determinant  spreading but incapable by 
itself of generating a pathogenic level of Thl  inflammatory 
cytokines. 
Passive Transfer of EAE with Spreading Determinants.  To de- 
termine  the  pathogenicity  of  consistent  intermolecular 
spreading to MBP  87-99,  the  ability  to transfer EAE into 
naive recipients was evaluated.  50 d  after immunization of 
The Determinant Spreading Cascade in Autoimmune Encephalomyelitis T
a
b
l
e
 
1
.
 
P
L
P
 
I
n
t
r
a
m
o
l
e
c
u
l
a
r
 
D
e
t
e
r
m
i
n
a
n
t
 
S
p
r
e
a
d
i
n
g
 
i
n
 
(
S
W
R
￿
 
1
 
M
i
c
e
*
 
a
f
t
e
r
 
I
m
m
u
n
i
z
a
t
i
o
n
s
 
w
i
t
h
 
p
1
3
9
-
1
5
1
~
 
S
e
q
u
e
n
c
e
 
o
f
 
P
L
P
 
1
2
1
-
1
7
4
 
2
4
9
-
2
7
3
 
1
7
3
-
1
9
8
 
K
G
R
 
G
 
S
1
q
,
 
G
Q
H
Q
A
H
S
L
E
P
,
.
V
C
H
C
L
 
G
K
W
L
G
 
H
P
D
K
F
V
G
 
I
 
T
Y
A
L
T
V
V
W
L
L
V
F
A
C
S
A
V
P
V
Y
 
T
L
V
S
L
L
T
F
M
 
I
A
A
T
Y
N
F
A
V
L
K
L
M
 
G
R
 
G
 
V
Y
I
Y
F
N
T
W
T
T
C
Q
S
 
I
A
F
P
S
K
T
S
A
S
 
I
 
G
S
 
D
a
y
 
7
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
H
C
L
G
K
W
L
G
 
H
P
D
K
F
V
G
 
I
 
T
Y
A
L
T
V
V
W
L
L
V
F
A
C
S
 
A
V
P
V
Y
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
C
H
C
L
G
K
W
L
G
H
P
D
K
F
V
G
 
I
 
T
Y
A
L
T
V
V
W
L
L
V
F
A
C
S
A
V
P
V
-
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
C
H
C
L
G
K
W
L
G
 
H
P
D
K
F
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
D
a
y
 
2
8
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
C
H
C
L
G
K
W
L
G
H
P
D
K
F
V
G
 
I
T
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
H
C
L
G
K
W
L
G
H
P
D
K
F
V
G
I
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
C
H
C
L
G
K
W
L
G
 
H
P
D
K
F
V
G
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
D
a
y
 
5
6
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
C
H
C
L
G
K
W
L
G
I
-
/
P
D
K
F
V
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
C
H
C
L
G
K
W
L
G
I
-
I
P
D
K
F
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
V
C
H
C
L
G
K
W
L
G
H
P
D
K
F
V
G
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
D
a
y
 
8
4
 
.
.
.
.
.
.
 
G
 
Q
H
Q
A
H
S
 
L
E
R
.
V
C
H
C
L
G
K
W
L
G
 
H
P
D
K
F
V
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
T
L
V
S
L
L
T
F
M
I
A
A
T
Y
N
F
 
.
.
.
.
.
.
.
.
.
 
K
G
P
,
-
G
 
S
 
R
G
Q
H
Q
A
H
S
 
L
E
P
,
.
V
C
H
C
L
G
I
Z
-
W
L
G
H
P
D
K
F
V
G
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
V
S
L
L
T
F
M
I
A
A
T
Y
N
F
A
V
 
.
.
.
.
.
.
.
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
V
C
H
C
L
G
K
W
L
G
H
P
D
K
F
V
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
L
V
S
L
L
T
F
M
I
A
A
T
Y
N
F
A
V
L
K
L
M
G
 
-
 
-
 
.
.
.
.
.
.
.
.
.
 
I
A
A
T
Y
N
F
A
V
L
K
L
M
G
R
.
G
 
.
.
.
.
.
.
.
.
.
 
I
A
A
T
Y
N
F
A
V
L
K
L
M
G
R
G
 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
.
.
.
.
.
.
.
.
.
 
I
A
A
T
Y
N
F
A
V
L
K
L
M
G
-
 
-
 
.
.
.
.
.
.
.
.
.
 
I
A
A
T
Y
N
F
A
V
L
K
L
M
G
-
 
-
 
.
.
.
.
.
.
.
.
.
.
 
A
A
T
Y
N
F
A
V
L
K
L
M
G
R
G
 
V
Y
I
Y
F
N
T
W
'
Y
F
C
Q
S
 
I
A
F
P
S
K
T
S
A
S
 
I
 
G
S
 
-
 
-
 
I
Y
F
N
T
W
T
T
C
Q
S
 
I
A
F
P
S
K
T
S
A
S
 
I
 
G
S
 
.
.
.
.
.
.
.
 
W
T
T
C
Q
S
 
I
A
F
P
S
K
T
S
A
 
.
.
.
.
 
*
D
a
t
a
 
s
h
o
w
 
t
h
e
 
r
e
s
u
l
t
s
 
o
f
 
t
h
r
e
e
 
i
n
d
e
p
e
n
d
e
n
t
l
y
 
p
e
r
f
o
r
m
e
d
 
e
x
p
e
r
i
m
e
n
t
s
 
i
n
 
w
h
i
c
h
 
s
p
l
e
e
n
s
 
w
e
r
e
 
r
e
m
o
v
e
d
 
f
r
o
m
 
o
n
e
 
m
o
u
s
e
 
o
n
 
d
a
y
s
 
7
,
 
2
8
,
 
5
6
,
 
a
n
d
 
8
4
 
a
f
t
e
r
 
p
1
3
9
-
1
5
1
 
i
m
m
u
n
i
z
a
t
i
o
n
 
a
n
d
 
t
e
s
t
e
d
 
f
o
r
 
p
r
o
l
i
f
e
r
a
t
i
v
e
 
r
e
s
p
o
n
s
e
s
 
t
o
 
a
 
p
i
n
 
s
e
r
i
e
s
 
o
f
 
P
L
P
 
p
e
p
t
i
d
e
s
.
 
T
e
s
t
 
w
e
l
l
s
 
c
o
n
t
a
i
n
i
n
g
 
1
5
 
l
.
L
g
/
m
i
 
o
f
 
o
n
e
 
p
i
n
 
1
2
-
m
e
r
 
P
L
P
 
p
e
p
t
i
d
e
 
w
e
r
e
 
c
o
n
s
i
d
e
r
e
d
 
p
o
s
i
t
i
v
e
 
w
h
e
n
 
t
h
e
i
r
 
s
t
i
m
u
l
a
t
i
o
n
 
i
n
d
e
x
 
w
a
s
 
a
t
 
l
e
a
s
t
 
t
w
o
 
t
i
m
e
s
 
b
o
t
h
 
t
h
e
 
S
D
 
a
n
d
 
t
h
e
 
m
e
a
n
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
o
f
 
c
o
n
t
r
o
l
 
w
e
l
l
s
 
w
i
t
h
o
u
t
 
p
e
p
t
i
d
e
.
 
T
h
e
 
c
r
i
t
e
r
i
a
 
f
o
r
 
i
d
e
n
t
i
f
y
i
n
g
 
a
n
t
i
g
e
n
i
c
 
d
e
t
e
r
m
i
n
a
n
t
s
 
o
f
 
P
L
P
 
r
e
q
u
i
r
e
d
 
t
h
a
t
 
p
o
s
i
t
i
v
e
 
p
r
o
h
f
e
r
a
t
i
v
e
 
r
e
s
p
o
n
s
e
s
 
b
e
 
g
e
n
e
r
a
t
e
d
 
b
y
 
a
t
 
l
e
a
s
t
 
t
h
r
e
e
 
a
d
j
a
c
e
n
t
 
1
2
-
m
e
r
s
.
 
;
t
D
a
t
a
 
s
h
o
w
 
s
p
l
e
n
o
c
y
t
e
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
o
n
 
d
a
y
s
 
a
f
t
e
r
 
i
m
m
u
n
i
z
a
t
i
o
n
,
 
n
o
t
 
d
a
y
s
 
a
f
t
e
r
 
E
A
E
 
o
n
s
e
t
.
 
A
l
l
 
(
S
W
R
￿
 
S
J
L
)
F
 
1
 
m
i
c
e
 
t
e
s
t
e
d
 
f
r
o
m
 
d
a
y
 
2
8
 
o
n
w
a
r
d
 
h
a
d
 
a
l
r
e
a
d
y
 
d
e
v
e
l
o
p
e
d
 
E
A
E
 
w
h
e
n
 
t
e
s
t
e
d
 
a
n
d
 
d
i
d
 
s
o
 
w
i
t
h
i
n
 
3
0
 
d
 
a
f
t
e
r
 
i
m
m
u
n
i
z
a
t
i
o
n
.
 
T
h
e
 
p
r
i
m
i
n
g
 
p
 
1
3
9
-
1
5
1
 
i
m
m
u
n
o
g
e
n
 
i
s
 
u
n
d
e
r
l
i
n
e
d
 
t
h
r
o
u
g
h
o
u
t
.
 
T
o
 
m
o
n
i
t
o
r
 
t
h
e
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
i
n
t
e
r
m
o
l
e
c
u
l
a
r
 
d
e
t
e
r
m
i
n
a
n
t
 
s
p
r
e
a
d
i
n
g
,
 
t
r
i
p
h
c
a
t
e
 
w
e
l
l
s
 
w
e
r
e
 
t
e
s
t
e
d
 
f
o
r
 
r
e
s
p
o
n
s
e
s
 
t
o
 
1
5
 
~
g
/
m
i
 
M
B
P
 
8
7
-
9
9
,
 
a
n
 
i
m
m
u
n
o
d
o
m
i
n
a
n
t
 
d
e
t
e
r
-
 
m
i
n
a
n
t
 
f
o
r
 
b
o
t
h
 
S
J
L
/
J
 
a
n
d
 
S
W
R
/
J
 
p
a
r
e
n
t
a
l
 
m
o
u
s
e
 
s
t
r
a
i
n
s
,
 
a
n
d
 
M
O
G
 
9
2
-
1
0
6
,
 
i
m
m
u
n
o
d
o
m
i
n
a
n
t
 
f
o
r
 
S
J
L
/
J
 
m
i
c
e
.
 
A
n
 
e
p
h
e
m
e
r
a
l
 
r
e
s
p
o
n
s
e
 
t
o
 
P
L
P
 
4
7
-
6
0
 
o
c
c
u
r
r
e
d
 
i
n
 
o
n
e
 
m
o
u
s
e
 
a
t
 
d
a
y
 
5
6
 
o
n
l
y
,
 
a
n
d
 
a
 
r
e
s
p
o
n
s
e
 
t
o
 
M
O
G
 
9
2
-
1
0
6
 
o
c
c
u
r
r
e
d
 
i
n
 
o
n
e
 
m
o
u
s
e
 
a
t
 
d
a
y
 
8
4
.
 
A
l
l
 
m
i
c
e
 
f
r
o
m
 
d
a
y
 
5
6
 
o
n
w
a
r
d
 
c
o
n
s
i
s
t
e
n
t
l
y
 
r
e
s
p
o
n
d
e
d
 
t
o
 
M
B
P
 
8
7
-
9
9
 
(
T
a
b
l
e
 
2
)
.
 
S
i
g
n
i
f
i
c
a
n
t
 
v
a
r
i
a
t
i
o
n
s
 
i
n
 
r
e
s
p
o
n
s
e
 
t
o
 
a
n
t
i
-
C
D
3
 
a
n
t
i
b
o
d
y
 
w
e
r
e
 
n
o
t
 
o
b
s
e
r
v
e
d
,
 
b
u
t
 
d
o
s
e
 
r
e
s
p
o
n
s
e
s
 
t
o
 
w
h
o
l
e
 
P
L
P
 
w
e
r
e
 
i
n
c
o
n
s
i
s
t
e
n
t
 
a
n
d
 
f
r
e
q
u
e
n
t
l
y
 
d
i
d
 
n
o
t
 
c
o
i
n
c
i
d
e
 
w
i
t
h
 
t
h
e
 
o
b
s
e
r
v
e
d
 
r
e
a
c
t
i
v
i
t
y
 
t
o
 
i
m
m
u
n
o
d
o
m
i
n
a
n
t
 
P
L
P
 
p
e
p
t
i
d
e
s
.
 Table 2.  Summary  of lntra and Intermolecular Sequential 
Determinant Spreading in (SWR￿  SJL)F  l Mice Immunized with 
PLP 139-151 
Day after immunization with PLP 139-151 
Sequence  7  28  56  84 
TaMe 3.  Passive  Transfer of EAE by Spleen Cells Activated with 
the Spreading Determinant MBP 87-99 
Number  Mean day 
of mice  of EAE  Mean 
Priming  Activating  with clinical  onset  clinical 
peptide  peptide  EAE  (range)  score 
PLP 139-151  +++  +++  +++  +++ 
PLP 249-273  + + -  + + +  + + + 
MBP 87-99  +++  +++ 
PLP 173-198  + + + 
Summary table showing determinant-spreading patterns from three in- 
dependently  performed  experiments in which  spleens were removed 
from one (SWRXSJL)F1 mouse on days 7, 28, 56, and 84 after p139- 
151 immunization and tested for proliferative responses to a pin series of 
PLP peptides (shown in detail in Table 1) and to the immunodominant 
encephalitogenic determinants MBP 87-99 and MOG 92-106.  +  vs - 
indicates response vs no response for a given mouse on each day indi- 
cated. 
(SWRXSJL)F 1 mice with p139-151,  spleen cells were  re- 
moved from EAE mice and stimulated in vitro with either 
MBP  87-99  or PLP  139-151.  Adoptive transfer of 5.0  ￿ 
107  cells resulted in acute EAE  in  three  out  of five naive 
(SWRXSJL)F  1  mice  receiving  MBP  87-99--stimulated 
spleen cells compared with six out of six recipients receiv- 
ing p139-151-activated cells (Table 3). The severity of dis- 
ease and time of onset were comparable in both groups of 
mice and demonstrated the pathogenic rather than protec- 
tive  nature  of  determinant  spreading  to  the  immuno- 
dominant MBP 87-99. 
Invariant Relationship between EAE Relapse~Progression and 
Determinant Spreading.  To determine whether the observed 
spreading pattern occurs within a given animal, spleen cell 
900  A  B  30 
o11o,  c. 
~300  0 
0~L.~  .... 
IL-2  IFNy  IL-4  IL-10  F  l  SWR/J SJL/J 
Cytokine  Antigen-Presenting  Cells 
Figure 2.  T cell activity in response to PLP 258-273. (A) Deficient in- 
flarmnatory  cytokine production by PLP 258-273 T cell fines. High levels 
ofThl cytokines are generated by (SWR￿  1 T cell fines specific for 
the encephafitogenic  p 139-151 determinant but not for the non encepha- 
litogenic p258-273. Cytokine levels  were assayed  by ELISA on supemates 
48 h after peptide activation. (/3) T cell fines generated to p258-273 in 
(SWR￿  mice show promiscuous MHC  restriction and respond 
(-+SE) when peptide is presented by APC from either parent. Prolifera- 
tion in response to 20 ~M p258-273 with (SWR￿  1 spleen feeder 
cells appears to represent the  additive responses of cultures containing 
APC of the individual parents. All background counts were ~<2,000 cpm. 
PLP 139-151  PLP 139-151  6/6  12.3 (10-14)  3.5 
PLP 139-151  MBP 87-99  3/5  15.7 (13-17)  3.5 
(SWR￿  mice were immunized with PLP 139-151. At 50 d after 
immunization, spleen cells were activated in vitro with either the p139- 
151 immunogen  or with the spreading determinant MBP 87-99. 5  X 
107 cells were injected intravenously into naive x-irradiated (450 rads) 
(SWRXSJL)F~ mice. 
responses to PLP pin peptides, MBP 87-99, and MOG  92- 
106  were  assessed  at  two  time  points  within  the  same 
mouse. Mice were hemisplenectomized for immune testing 
28  d  after  p139-151  immunization.  After  recovery from 
surgery,  the  mice  were  weighed  and  evaluated  daily for 
neurologic impairment, and at day 84 the remaining half of 
each spleen was retested for responses to all peptides. Five 
of eight  mice  developed at  least  one  clinical relapse and 
showed progression of clinical disease (Table 4). Moreover, 
all  five  relapsing-progressive mice  showed  a  determinant 
spreading  pattern  virtually identical to  that  described  for 
nonsurgically treated mice (Table 2).  In contrast, the three 
mice that  did not  develop clinical relapse and progression 
also failed to show spreading of recognition to the  domi- 
nant encephalitogenic peptides MBP  87-99  and PLP  173- 
198.  Thus,  it  appears  that  an  invariant  relationship  exists 
between clinical relapse/progression and spreading of self- 
recognition  to  new  immunodominant  encephalitogenic 
determinants. 
Prevention of EAE Progression by Peptide-specific Inhibition of 
Determinant Spreading.  The predictable sequential spread- 
ing pattern in (SWRXSJL)F 1 mice offered an opportunity 
for  directly  addressing  the  pathogenicity  of determinant 
spreading. 10 d  after onset of EAE, mice were tolerized by 
intravenous injection with either the primary spreading de- 
terminant  MBP  87-99  or with  PLP  104-117,  an  equally 
potent  encephalitogenic  determinant  for  (SWRXSJL)F1 
mice  (21,  29)  not involved in the observed spreading pat- 
tern.  The  results  obtained by blinded evaluation  indicate 
that mice tolerized to the spreading MBP  87-99  determi- 
nant  showed  consistent  improvement  in  mean  clinical 
score  and  delayed progression  of clinical disease,  whereas 
mice tolerized to the non-spreading PLP 104-117 determi- 
nant  continued  their progression  to  disability (Fig.  3  A). 
The  clinical improvement  of MBP  87-99  tolerized mice 
was accompanied by a corresponding significant inhibition 
(P --  0.0414)  of MBP  87-99  DTH  as measured by deter- 
minant-specific ear swelling (Fig.  3  B).  The  inhibition of 
DTH  was antigen specific to the extent that no differences 
1782  The Determinant Spreading Cascade in Autoimmune Encephalomyelitis Table 4.  Determinant  Spreading in Hemisplenctomized (SWRXSJL)F  I Mice: Invariant Relationship between Spreading and 
Relapse/Progression 
Hemisplenectomy 28 d 
after immunization 
with PLP 139-151 
Proliferative responses to spreading determinants 
PLP 139-151  PLP 258-273  MBP 87-99  PLP 173-198 
Relapsing mice (n =  5) 
Day 28 responses  + + + + +  + + + -  - 
Day 84 responses  + + + + +  + + + + + 
Nonrelapsing mice (n =  3) 
Day 28 responses  + + +  + -  - 
Day 84 responses  + + +  + -  - 
+++++  ++++-- 
28 d after immunization with PLP 139-151,  (SWRXSJL)F1  mice were hemisplenectomized and tested  for proliferation to a pin peptide series for 
PLP as well as to MBP 87-99 and MOG 92-106. All mice had clinical EAE by day 28. Hemisplenectomized mice were weighed and examined daily 
for neurologic deficit.  On day 84 after immunization, the remaining spleens were removed and retested for proliferative responses to the same pep- 
tides. All five mice that developed clinical relapse and progression  showed determinant spreading  to MBP 87-99, and four out of five mice showed 
spreading  responses to PLP 173-198.  All three mice that failed to relapse and progress also failed to show spreading  of the autoimmune response  to 
either MBP 87-99 or PLP 173-198. 
Figure 3.  Inhibition of disease progression by intravenous  induction of 
tolerance  after onset of EAE to spreading vs nonspreading  determinants. 
(A) 10 d after EAE onset, (SWRXSJL)F1 mice were tolerized by intrave- 
nous injection of 300 ~g of either the immunodominant spreading deter- 
minant MBP 87-99 or PLP 104-117, a highly encephalitogenic  immuno- 
dominant determinant  (21, 29)  not involved in  determinant  spreading. 
Mice were examined daily by a person  blinded to treatment  protocols. 
Mice tolerized  to the spreading determinant  MBP 87-99  failed to show 
clinical progression  of disease (+SE).  (B) The clinical improvement di- 
recdy correlated  with inhibition of DTH responses (day 36-40 after on- 
set) to the spreading determinant  MBP 87-99.  No difference in the DTH 
response to the priming immunogen PLP  139-151  was evident between 
both groups oftolerized mice. However, the DTH response (+SE) to the 
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were  observed  between  both  groups  of tolerized  mice  in 
DTH  responses to the priming p139-151  immunogen. 
In addition tO intravenous injection of peptide,  (SWR.￿ 
SJL)F  1 mice  were  tolerized  7  d  after  EAE  onset  by  intra- 
peritoneal immunization in an IFA emulsion containing ei- 
ther  the  spreading  MBP  87-99  determinant,  the  non- 
spreading  control  encephalitogen  PLP  104-117,  or  IFA 
emulsion  alone.  Induction  of MBP  87-99  tolerance  after 
EAE  onset  resulted  in  a  marked  therapeutic  effect  (Fig.  4 
A). By day  32,  a  significant improvement in mean  clinical 
score  was  evident in  mice  tolerized  to  MBP  87-99  com- 
pared with sham-  (P =  0.0105)  or PLP  104-117-tolerized 
(P  =  0.0204)  mice.  No  significant differences were appar- 
ent between PLP  104-117-  and  sham-tolerized mice. The 
clinical  improvement  in  MBP  87-99-tolerized  mice  was 
accompanied  by  a  significant  inhibition  (P  =  0.0035)  in 
splenocyte  proliferative  responses  to  MBP  87-99,  but  not 
to the p139-151  priming determinant  (Fig. 4  B). 
Histopathology  in Peptide-tolerized EAE Mice.  At 32-35  d 
after EAE onset, peptide-tolerized (SWR.XSJL)F 1 mice were 
killed,  and  the  brains  and  spinal  cords  were  examined  for 
the  appearance  of inflammatory  infiltrates  and  demyelina- 
tion.  Mice tolerized to the spreading MBP  87-99  determi- 
nant  consistently  showed  inflammatory  changes  that  were 
qualitatively less severe than  those  observed in mice toler- 
ized  to  the  nonspreading  PLP  104-117  encephalitogen. 
MBP  87-99-tolerized  mice had  fewer CNS  inflammatory 
infiltrates  and  markedly  less  severe  demyelination  com- 
pared with mice tolerized to PLP  104-117  (Fig. 5). 
spreading determinant  MBP 87-99  was significantly lower (P =  0.0414) 
in mice tolerized  to  MBP 87-99  compared with mice tolerized  to the 
nonspreading PLP 104-117. Figure 4.  Clinical improvement after peptide-specific inhibition of de- 
ternfinant spreading. (A) 7 d after EAE onset, (SWR￿  1 mice were 
immunized with 100 I~g i.p. of either the spreading determinant MBP 
87-99, the nonspreading determinant PLP 104-117, or sham injections 
with IFA emulsion alone. Mice were evaluated in a blinded manner as 
described in Materials and Methods. By day 32, a significant improve- 
~nent in mean clinical score (~SE) was evident in mice tolerized to MBP 
87-99 compared  with sham- (P = 0.0105) or PLP 104-117-tolerized (P = 
0.0204) mice. No significant clinical differences were apparent between 
PLP 104-117- and sham-tolerized mice. In contrast to the immediate 
therapeutic effectiveness observed after intravenous injection of MBP 
87-99 (Fig. 3 A), intraperitoneal immunization with MBP 87-99 in IFA 
produced a more delayed effect consistent  with immune priming. (B) The 
clinical improvement observed in MBP 87-99-tolerized mice correlated 
with a significant inhibition (P =  0.0035) in splenocyte proliferative re- 
sponses (days 32-35 after onset) to MBP 87-99 compared with mice tol- 
erized with  the  nonspreading encephalitogenic PLP  104-117 (+SE). 
However, no differences  were apparent between both groups ofpeptide- 
tolerized mice in their splenocyte proliferative responses to the priming 
PLP 139-151 irrtmunogen. It is worth noting that intermolecular spread- 
ing to MBP 87-99 resulted in a level of autoreactivity on a par with that 
directed against the priming p139-151 determinant as indicated by the 
ability to mediate passive transfer of  EAE (Table 3) and DTH (Fig. 3 /3). 
Moreover, splenocyte  proliferative responses to MBP 87-99 were actually 
greater than those directed against p 139-151. 
Discussion 
This study shows that determinant  spreading during the 
development of autoinmlune  disease is an ordered physio- 
logic process in which defined self-determinants  are recog- 
nized  in  a  sequential  predictable  manner.  Moreover,  the 
mediation  of passively transferred EAE with spreading de- 
terminants, the invariant relationship between spreading and 
chronicity, and the therapeutic effect on disease progression 
after  determinant-specific  inhibition  of  spreading  estab- 
lishes an essential pathogenic role of determinant spreading 
in the progression of autoimmunity and provides a founda- 
tion for therapeutic intervention of ongoing disease. 
Although the detailed  mechanisms responsible for exac- 
erbation  of autoimmune  demyelinating  disease  are  pres- 
ently unclear, numerous studies have implicated bursts ofT 
cell-inflammatory cytokine activity before  or during early 
stages of relapse.  Increased IFN-~ and TNF-ot activity (30) 
and increased  TNF-ct and TNF-[3 mRNA  levels  (31)  oc- 
cur in PBL of MS patients  before both clinical relapse and 
active  magnetic  resonance  scans  (31).  Relapse  in  MS  has 
also been associated with  decreased expression of the anti- 
inflammatory cytokines TGF-[3 and IL-10 in MS (31). Sim- 
ilarly,  inflammatory cytokines have  been  demonstrated  in 
the CNS during active EAE (32-34), whereas recovery has 
been associated with  concomitant  decreased  CNS  expres- 
sion of IFN-% IL-2, IL-4, and IL-6 and increased expres- 
sion of IL-10 mRNA  (35). Furthermore,  bursts of mRNA 
expression  for  inflammatory  chemokines  occur  immedi- 
ately before the initiation  of both EAE onset  (36,  37)  and 
relapse  (38)  in  SjL/j  mice,  whereas  abrupt  decreased  ex- 
pression  often occurs during remission.  However,  perhaps 
the most convincing evidence to date for immune  media- 
tion of relapse are the results obtained from an IFN-~/clin- 
ical trial that produced a high enough rate of MS relapse to 
terminate treatment  (39). 
The  results  of this  study indicate  that the  inflammatory 
cytokine and chemokine activity associated with relapse and 
chronicity ofautoimmune demyelination are due at least in 
part  to  spreading  of Thl  recognition  to  new  myelin self- 
determinants.  However,  numerous  reports have associated 
failure  to  relapse  with  innate  immunoregnlatory  mecha- 
nisms  that  appear  to  target  immunogen-primed  autoreac- 
tive T  cells. Apoptosis (40, 41), CD4  § anti-TCR inhibitory 
cells  (42-44),  and perhaps  CD8 +  cells  (45,  46)  have  been 
implicated in downregulation of the response to the prim- 
ing immunogen  and may explain  the  nonrelapsing  nature 
of EAE in Lewis rats and in PL/J and B10.PL mice. 
Conversely,  such  inhibitory  mechanisms  may  be  defi- 
cient in relapsing and chronic progressive EAE models, thus 
predisposing to a sustained pathogenic response to the prim- 
ing immunogen with  subsequent  transfer of autoreactivity 
to  spreading  determinants.  Furthermore,  it  is  conceivable 
that patients with single demyelinating episodes (e.g., optic 
neuritis)  have  intact  immunoregulatory  mechanisms  that 
result  in  aborted  autoreactivity,  whereas  patients  that  de- 
velop MS  fail  to  down-regulate  their  initial  self-reactivity 
and progress  by spreading  the  response  to new self-deter- 
minants.  From this perspective,  chronic progression of au- 
toimmune  demyelinating  disease  would appear  to  require 
that a threshold inflammatory response to the priming im- 
munogen be maintained long enougl~ to allow the transfer 
of autoimmune  targeting to  new  determinants.  Autoreac- 
tivity would be perpetuated by serial transfer of  recognition 
through a determinant-spreading cascade. In this context, it 
is worth noting that spreading to the nondominant  p249- 
273 occurs by day 28, coinciding with or immediately fol- 
lowing EAE onset. This suggests that p249-273 may repre- 
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(￿  luxol fast blue-cresyl violet)  of the dorsal columns of cervical spinal cords ftom mice tolerized intraperitoneally with pepfde/IFA emulsion 7 d af- 
ter EAE onset. Mice tolerized with MBP 87-99 consistently showed less severe inflammation and demyelination than mice tolerized with PLP 1044117. 
(A) Representative mouse tolerized with the spreading determinant MBP 87-99. Demyelination is not apparent 32 d after EAE onset. (B) In contrast, 
EAE mouse tolerized with the nonspreading PLP 104-117 determinant shows an extensive  area of demyelination  involving  most of  the dorsal columns  33 d 
after EAE onset. Bar, 50 g~m. 
sent an "enhancer" determinant, incapable of mediating EAE 
induction  by itself but capable of amplifying and sustaining 
the  early  inflammatory  response  directed  initially  against 
the  priming p139-151  immunogen.  This type of determi- 
nant-mediated  inflammatory enhancement may thereby as- 
sist  in  spreading  the  response  to  the  immunodominant 
MBP  87-99,  a  determinant  completely capable of mediat- 
ing and maintaining pathogenicity. 
The  order in which  determinants  are recognized  during 
spreading  does  not  follow  the  traditional  immunodomi- 
nant---)nondominant  hierarchy,  nor  does  it  favor  in  any 
sense an intramolecular  bias.  Spreading  to PLP  249-273,  a 
nondominant  determinant  according to traditional  criteria, 
occurs  before  broadening  of the  response  to  the  immu- 
nodominant peptides MBP 87-99 and PLP 173-198.  Thus, 
the  dominant  recognition  of p249-273  during  the  flow of 
autoimmune determinant spreading stands in direct conflict 
with  its  nondominant  character  as  traditionally  defined. 
However,  traditional  criteria  for  defining  dominant/non- 
dominant antigenic peptides are based on relative responses 
to  exogenous  proteins  such  as  hen  egg-white  lysozyme 
(47-49).  It  is  not  surprising,  therefore,  that  self-determi- 
nants having native antigen  depots are not recognized dur- 
ing  the  development  of autoimmune  disease  according  to 
criteria  obtained  from  exogenous  immunizations.  In  es- 
sence,  spreading  flows  from  one  determinant  to  another 
based on internal recognition patterns that appear to reflect 
factors not involved in the recognition of non-self proteins, 
such  as processing  and  determinant  availability within  the 
target  organ.  Thus,  the  order  in  which  determinants  are 
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recognized  during  the  development  of autoimmunity  re- 
flects an innate spreading dominance based on an immuno- 
logic  bias  that  appears  to  be  independent  of traditional 
dominant/nondominant  criteria. 
Responses  to  the  epitope-mapping  PLP  peptide  series 
reveals an extraordinary plasticity inherent  in immune rec- 
ognition of autoreactive proteins. At least four components 
constitute  the  observed  plasticity  of self-recognition:  (a) 
recognition  of broad  protein  regions  incorporating  core 
and  flanking  sequences  of encephalitogenic  determinants; 
this  pattern  is typically  characteristic  of early self-recogni- 
tion  events  initiated  by  either  exogenous  priming  or  en- 
dogenous  spreading  (Table  1);  (b)  focusing  of recognition 
to core sequences within each protein region;  (c) shifting of 
epitope responses within  each region;  and  (d)  spreading  of 
the  response to new regions incorporating  new  encephali- 
togenic core determinants.  In addition,  the development of 
ephemeral  aborted  responses  (e.g.,  the  response  to  PLP 
47-60 in one mouse on day 56 only) further adds to the in- 
herent supple features of self-recognition. 
It appears that immunization  with a discrete peptide  de- 
terminant is sufficient to consistently induce a response to a 
sequence adjacent to the priming determinant in the native 
protein but not involved in the initial immunization.  This 
implies that immune  recognition  of adjacent  self-determi- 
nants  is  cognate  and  that  an  innate  relationship  exists be- 
tween recognition  of core determinants  and recognition  of 
their adjacent flanking sequences.  The nature  of such rela- 
tionships  may  reflect  protein  sequence  motifs  requiring 
structural  or functional  complementary ligands,  as has been suggested  (50-52).  The  ephemeral  and  shifting  nature  of 
flanking region recognition is also of interest and may rep- 
resent  aborted  autoimmunity  that  fails  to  develop  patho- 
genic consequences.  Nevertheless,  the plasticity of the ob- 
served recognition patterns indicates that autoimmune disease 
involves  self-recognition  events  characterized  by a  supple 
dynamic developmental immune agenda. This dynamic para- 
digna  provides  a  rationale  for  therapeutic  intervention  at 
each predictable stage in the development ofautoimmunity. 
Recent chnical improvements have enabled the identifi- 
cation of patients with single episodes of idiopathic mono- 
symptomatic demyehnating syndromes at high risk for pro- 
gressing to definite MS (53). Our preliminary results indicate 
that such patients have a high rate of self-recognition plas- 
ticity and show patterns of reactivity remarkably similar to 
those described in this study. Such shifting patterns of self- 
recognition may be responsible for the observed changes in 
T  cell repertoire restriction occurring in patients with optic 
neuritis  who ultimately develop MS  (54).  The coaccumu- 
lation  of neurologic  deficit  and promiscuous  self-determi- 
nant  recognition  implies  that  early  treatment  of autoim- 
mune  demyehnating  disease  would  be most desirable.  To 
this  end,  the  predictable  and  sequential  nature  of self-rec- 
ognition plasticity may serve both to target and to monitor 
the  effectiveness  of therapeutic  strategies  used  for  early 
treatment of MS and related CNS inflammatory abnormal- 
ities. 
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